Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer

被引:20
|
作者
Cai, Yaxiong [1 ]
Zhang, Jinxia [1 ]
Lao, Xuejun [2 ]
Jiang, Haowu [1 ]
Yu, Yunfei [1 ]
Deng, Yanrui [1 ]
Zhong, Jiangchuan [1 ]
Liang, Yiye [1 ]
Xiong, Likuan [3 ]
Deng, Ning [1 ,3 ]
机构
[1] Jinan Univ, Biomed Translat Inst, Guangdong Prov Key Lab Mol Immunol & Antibody Eng, 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China
[2] Jinan Univ, Sch Clin 1, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China
[3] Jinan Univ, Affiliated Hosp, Shenzhen Key Lab Birth Defects Baoan Maternal & C, Shenzhen, Peoples R China
来源
CANCER SCIENCE | 2016年 / 107卷 / 08期
关键词
Breast cancer; ds-Diabody; FGF-2; Pichia pastoris; tumor angiogenesis; MONOCLONAL-ANTIBODIES; TUMOR ANGIOGENESIS; IN-VIVO; BIOLOGICAL-ACTIVITY; FACTOR RECEPTORS; PICHIA-PASTORIS; FV FRAGMENTS; VEGF-A; PROTEIN; FGF-2;
D O I
10.1111/cas.12981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibroblast growth factor-2 (FGF-2) is one of the most important angiogenic factors to promote tumor growth, progression and metastasis. Neutralizing antibodies against FGF-2 may suppress the growth of tumor cells by blocking the FGF-2 signaling pathway. In this study, a disulfide-stabilized diabody (ds-Diabody) that specifically targets FGF-2 was designed. Compared to its parent antibody, the introduction of disulphide bonds in the diabody could significantly increase the stability of ds-Diabody and maintain its antigen binding activity. The ds-Diabody against FGF-2 could effectively inhibit the tube formation and migration of vascular endothelial cells and block the proliferation and invasion of human breast cancer cells. In the mouse model of breast cancer xenograft tumors, the ds-Diabody against FGF-2 could significantly inhibit the growth of tumor cells. Moreover, the densities of microvessels stained with CD31 and lymphatic vessels stained with LYVE1 in tumors showed a significant decrease following treatment with the ds-Diabody against FGF-2. Our data indicated that the ds-Diabody against FGF-2 could inhibit tumor angiogenesis, lymphangiogenesis and tumor growth.
引用
收藏
页码:1141 / 1150
页数:10
相关论文
共 50 条
  • [31] Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
    Brown, Wells S.
    Tan, Li
    Smith, Andrew
    Gray, Nathanael S.
    Wendt, Michael K.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) : 2096 - 2106
  • [32] miR-203 facilitates tumor growth and metastasis by targeting fibroblast growth factor 2 in breast cancer
    He, Shuqian
    Zhang, Guihui
    Dong, He
    Ma, Maoqiang
    Sun, Qing
    ONCOTARGETS AND THERAPY, 2016, 9 : 6203 - 6210
  • [33] Fibroblast growth factor-2 up-regulates telomerase activity in endothelial cells
    Kurz, DJ
    Decary, S
    Hong, Y
    Erusalimsky, JD
    EUROPEAN HEART JOURNAL, 2001, 22 : 136 - 136
  • [34] Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2
    Sahni, A
    Francis, CW
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (06) : 1271 - 1277
  • [35] Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2
    Presta, Marco
    Foglio, Eleonora
    Schuind, Ander Churruca
    Ronca, Roberto
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [36] Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor
    Sweeny, Larissa
    Liu, Zhiyong
    Lancaster, William
    Hart, Justin
    Hartman, Yolanda E.
    Rosenthal, Eben L.
    LARYNGOSCOPE, 2012, 122 (07): : 1539 - 1544
  • [37] Fibroblast growth factor-2 mediates transforming growth factor-β action in prostate cancer reactive stroma
    Yang, F.
    Strand, D. W.
    Rowley, D. R.
    ONCOGENE, 2008, 27 (04) : 450 - 459
  • [38] Fibroblast growth factor-2 mediates transforming growth factor-β action in prostate cancer reactive stroma
    F Yang
    D W Strand
    D R Rowley
    Oncogene, 2008, 27 : 450 - 459
  • [39] Distribution and prognostic value of the fibroblast growth factor-2 low-affinity binding sites in human breast cancer
    Blanckaert, VD
    Hornez, L
    Hebbar, M
    Louchez, MM
    Hondermarck, H
    Peyrat, JP
    ANTICANCER RESEARCH, 2000, 20 (5C) : 3913 - 3918
  • [40] Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors
    Berry, D
    Kwan, CP
    Shriver, Z
    Venkataraman, G
    Sasisekharan, R
    FASEB JOURNAL, 2001, 15 (06): : 1422 - +